ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 948

Application of a Diagnostic Algorithm to Identify Inflammatory Myopathy in Systemic Sclerosis

Vandana Bhushan1,2, Adam Maundrell1, Charlotte Proudman1,2, Leah McWilliams1, Llew Spargo1, Robert Metcalf1, Jennifer Walker3, Mandana Nikpour4,5, Wendy Stevens4, Vidya Limaye1,2 and Susanna Proudman1,2, 1Rheumatology Unit, Royal Adelaide Hospital, South Australia, Adelaide, Australia, 2Discipline of Medicine, University of Adelaide, South Australia, Adelaide, Australia, 3Flinders University of South Australia, Adelaide, Australia, 4St Vincent's Hospital, Melbourne, Victoria, Melbourne, Australia, 5Department of Medicine, University of Melbourne, Victoria, Melbourne, Australia

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: ,

Session Information

Date: Sunday, November 5, 2017

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics I

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose:

Muscle involvement in systemic sclerosis (SSc) is under-recognised and poorly understood. Reported prevalence varies up to 15%, reflecting lack of consistent definition, the heterogeneous spectrum of muscle involvement, ranging from non-specific myopathic changes to idiopathic inflammatory myopathies such as polymyositis, but also lack of a standardised approach to detection. Early diagnosis of inflammatory myopathy by muscle biopsy is important to guide immunosuppressive therapy to minimise irreversible loss of muscle power and function. We sought to determine the prevalence of inflammatory myopathy in patients with SSc assessed annually for features of muscle involvement according to a standardised algorithm.

Methods:

Consecutive patients with SSc, according to the 1980 ACR or LeRoy and Medsger criteria, enrolled in the Australian Scleroderma Cohort Study (ASCS) since 2007, are assessed annually for features of myopathy: proximal muscle weakness based on the Medical Research Centre scale and elevated creatine kinase (CK) > 150 U/L. No specific guidelines for further investigation are followed. In a subset of patients from a single ASCS centre, if proximal weakness and/or elevated CK were present, myositis immunoblot for myositis specific antibodies (MSA) and/or MRI of upper or lower limbs for increased T2 signal or fatty infiltration and atrophy were performed; positive findings prompted a muscle biopsy. Features of patients with and without histopathological features of inflammation on biopsy were compared.

Results:

Among 1197 patients enrolled in the ASCS, 176 (14.7%) had elevated CK with or without weakness at any time during follow up, 128 (10.7%) had weakness with a normal CK, and 18 (1.5%) patients had biopsy-proven inflammatory myopathy. In a separate ASCS cohort of 333 patients in South Australia, 89 of 323 (27.6%) had elevated CK, 83 of 326 (25.5%) had proximal weakness and 34 (10.2%) were selected for muscle biopsy. Abnormalities were present in all 34 biopsies, with inflammatory myopathy (polymyositis, 10; dermatomyositis, 4; inclusion body myositis, 3; necrotising, 1; other, 2) confirmed in 20 (58.8%) and nonspecific features of myopathy reported in 14.

Among the biopsied patients, incidence of diffuse cutaneous subtype and levels of CK were significantly higher in those with inflammatory compared with non-inflammatory myopathy (Table 1). Immunosuppressive use at time of biopsy was similar in the two groups.

Table 1: Characteristics of SSc patients selected for muscle biopsy

Inflammatory myopathy

n = 20

Non-inflammatory myopathy

n = 14

P value1

Diffuse SSc

6

0

0.031

SSc antibodies:

ACA

Scl70

RNA polymerase III

RNP

10/20

3

2

1

4

9/14

2

2

3

2

0.500

Immunosuppressive therapy at time of biopsy

9

9

0.147

Elevated CK

14

7

0.238

CK level U/L (median, IQR)

436 (243-571)

132 (63-383)

0.0232

Proximal weakness

15

11

1.000

Myositis immunoblot +ve:

Ro52

Mi-2

Ku

PM-Scl75

Jo-1

SRP

PL7

PL12

10/17

7

1

1

2

1

1

1

1

4/10

2

0

1

1

1

0

0

0

0.440

Increased T2 signal on MRI muscle

6/7

2/7

0.103

IQR, interquartile range

1Fisher’s exact test except where indicated. 2Mann Whitney U.

Conclusion:

A diagnostic algorithm including MSA and MRI, detected biopsy-proven muscle involvement in 10.2% of patients with SSc and increased the detection of inflammatory myopathy to 6% of patients compared with 1.5% in the whole ASCS cohort.

Disclosure: V. Bhushan, None; A. Maundrell, None; C. Proudman, None; L. McWilliams, None; L. Spargo, None; R. Metcalf, None; J. Walker, Actelion Australia, Bayer, CSL Biotherapies, GlaxoSmithKline Australia and Pfizer, 2; M. Nikpour, Actelion Australia, Bayer, CSL Biotherapies, GlaxoSmithKline Australia and Pfizer, 2; W. Stevens, Actelion Australia, Bayer, CSL Biotherapies, GlaxoSmithKline Australia and Pfizer, 2; V. Limaye, None; S. Proudman, Actelion Australia, Bayer, CSL Biotherapies, GlaxoSmithKline Australia and Pfizer, 2,Actelion Australia, 8.

To cite this abstract in AMA style:

Bhushan V, Maundrell A, Proudman C, McWilliams L, Spargo L, Metcalf R, Walker J, Nikpour M, Stevens W, Limaye V, Proudman S. Application of a Diagnostic Algorithm to Identify Inflammatory Myopathy in Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/application-of-a-diagnostic-algorithm-to-identify-inflammatory-myopathy-in-systemic-sclerosis/. Accessed .

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/application-of-a-diagnostic-algorithm-to-identify-inflammatory-myopathy-in-systemic-sclerosis/